These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19442324)

  • 21. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On target to dual block RAS?
    Papadopoulos DP; Papademetriou V; Makris TK
    Angiology; 2009 Dec-2010 Jan; 60(6):739-49. PubMed ID: 19144653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Left-ventricular hypertrophy and coronary artery disease.
    Pierdomenico SD
    Am J Hypertens; 2007 Oct; 20(10):1036-7. PubMed ID: 17903684
    [No Abstract]   [Full Text] [Related]  

  • 27. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies.
    Fagard RH; Celis H; Thijs L; Wouters S
    Hypertension; 2009 Nov; 54(5):1084-91. PubMed ID: 19770405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic role of RAS blockade in chronic heart failure.
    Werner CM; Böhm M
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):167-77. PubMed ID: 19124420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic options in minimizing left ventricular hypertrophy.
    Devereux RB
    Am Heart J; 2000 Jan; 139(1 Pt 2):S9-14. PubMed ID: 10618582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.
    Edwards NC; Steeds RP; Stewart PM; Ferro CJ; Townend JN
    J Am Coll Cardiol; 2009 Aug; 54(6):505-12. PubMed ID: 19643310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early recognition and treatment of hypertensive heart disease.
    Mitchell JA; Ventura HO; Mehra MR
    Curr Opin Cardiol; 2005 Jul; 20(4):282-9. PubMed ID: 15956824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The renin-angiotensin system in left ventricular remodeling.
    Blaufarb IS; Sonnenblick EH
    Am J Cardiol; 1996 May; 77(13):8C-16C. PubMed ID: 8638527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is RAS blockade routinely indicated in hypertensive kidney transplant patients?
    Salzberg DJ
    Curr Hypertens Rep; 2007 Nov; 9(5):422-9. PubMed ID: 18177591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta blockers & left ventricular hypertrophy regression.
    George T; Ajit MS; Abraham G
    Indian Heart J; 2010; 62(2):139-42. PubMed ID: 21180305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation.
    Plante E; Lachance D; Beaudoin J; Champetier S; Roussel E; Arsenault M; Couet J
    Circ Heart Fail; 2009 Jan; 2(1):25-32. PubMed ID: 19808312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin receptor blockers: evidence for preserving target organs.
    Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
    Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.